This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Elliott, W. J. Articles by Murphy, M. B. Search for Related Content PubMed PubMed Citation Articles by Elliott, W. J. Articles by Murphy, M. B.

Circulation, Vol 81, 970-977, Copyright © 1990 by American Heart Association

ARTICLES

Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension

WJ Elliott, RR Weber, KS Nelson, CM Oliner, MT Fumo, DD Gretler, GR McCray and MB Murphy
Committee on Clinical Pharmacology, University of Chicago, IL 60637.

The renal and hemodynamic effects of intravenously administered fenoldopam mesylate, a novel dopamine-1 receptor agonist, were compared with those of sodium nitroprusside in 28 patients (18 male; 26 black, two white; average age, 49 +/- 3 years) with an average blood pressure of 219/137 mm Hg, most of whom presented with acute target organ damage. Fenoldopam and nitroprusside lowered blood pressure safely to an average pressure of 176/105 mm Hg; highly significant dose-response relations were found for the 13 patients receiving fenoldopam and the 15 receiving nitroprusside. Volume and sodium, potassium, and creatinine concentrations were measured in freely voided urine specimens both before and during intravenous therapy. In the fenoldopam- treated patients, there were significant increases in urinary flow (92 +/- 21 to 168 +/- 37 ml/hr, p less than 0.003), sodium excretion (227 +/- 73 to 335 +/- 90 mu eq/min, p less than 0.001), and creatinine clearance (70 +/- 11 to 93 +/- 13 ml/hr, p less than 0.003). In the nitroprusside-treated group, however, all these parameters decreased, but not significantly. For direct comparison of the two agents, the increments in urinary flow rate (+76 +/- 20 vs. -16 +/- 15 ml/hr, fenoldopam vs. nitroprusside), sodium excretion (+109 +/- 28 vs. -39 +/- 28 mu eq/min), and creatinine clearance (+23 +/- 6 vs. -11 +/- 7 ml/min) were significantly greater (p less than 0.001 for each) in the fenoldopam-treated group. Significant differences were also obtained when these parameters were calculated as percentage increase over baseline. Fenoldopam and nitroprusside are effective therapies for severe, accelerated, or malignant hypertension, but fenoldopam had additional salutary renal effects in these patients.

This article has been cited by other articles:

				D. Rhoney and W. F. Peacock Intravenous therapy for hypertensive emergencies, part 2 Am. J. Health Syst. Pharm., August 15, 2009; 66(16): 1448 - 1457. [Abstract] [Full Text] [PDF]

				P. E. Marik and J. Varon Hypertensive Crises: Challenges and Management Chest, June 1, 2007; 131(6): 1949 - 1962. [Abstract] [Full Text] [PDF]

				W. C. Oliver Jr, G. A. Nuttall, K. J. Cherry, P. A. Decker, T. Bower, and M. H. Ereth A Comparison of Fenoldopam with Dopamine and Sodium Nitroprusside in Patients Undergoing Cross-Clamping of the Abdominal Aorta Anesth. Analg., October 1, 2006; 103(4): 833 - 840. [Abstract] [Full Text] [PDF]

				B. Makkad and S. Pilling Management of Thoracic Aneurysm Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2005; 9(3): 227 - 240. [Abstract] [PDF]

				T. Bove, G. Landoni, M. Grazia Calabro, G. Aletti, G. Marino, E. Cerchierini, G. Crescenzi, and A. Zangrillo Renoprotective Action of Fenoldopam in High-Risk Patients Undergoing Cardiac Surgery: A Prospective, Double-Blind, Randomized Clinical Trial Circulation, June 21, 2005; 111(24): 3230 - 3235. [Abstract] [Full Text] [PDF]

				A. Asif, D. L. Epstein, and M. Epstein Dopamine-1 Receptor Agonist: Renal Effects and Its Potential Role in the Management of Radiocontrast-Induced Nephropathy J. Clin. Pharmacol., December 1, 2004; 44(12): 1342 - 1351. [Abstract] [Full Text] [PDF]

				M. Ranucci, G. Soro, N. Barzaghi, A. Locatelli, G. Giordano, A. Vavassori, A. Manzato, C. Melchiorri, T. Bove, G. Juliano, et al. Fenoldopam Prophylaxis of Postoperative Acute Renal Failure in High-Risk Cardiac Surgery Patients Ann. Thorac. Surg., October 1, 2004; 78(4): 1332 - 1337. [Abstract] [Full Text] [PDF]

				J. W Devlin, M. L Seta, S. Kanji, and A. L Somerville Fenoldopam Versus Nitroprusside for the Treatment of Hypertensive Emergency Ann. Pharmacother., May 1, 2004; 38(5): 755 - 759. [Abstract] [Full Text] [PDF]

				N. Sato, K. A. Tanaka, F. Szlam, A. Tsuda, M. E. Arias, and J. H. Levy The Vasodilatory Effects of Hydralazine, Nicardipine, Nitroglycerin, and Fenoldopam in the Human Umbilical Artery Anesth. Analg., February 1, 2003; 96(2): 539 - 544. [Abstract] [Full Text] [PDF]

				A. A. Chamsuddin, K. J. Kowalik, H. Bjarnason, C. A. Dietz, M. S. Rosenberg, M. D. Gomes, C. M. McDermott, and D. W. Hunter Using a Dopamine Type IA Receptor Agonist in High-Risk Patients to Ameliorate Contrast-Associated Nephropathy Am. J. Roentgenol., September 1, 2002; 179(3): 591 - 596. [Abstract] [Full Text] [PDF]

				M. B. Murphy, C. Murray, and G. D. Shorten Fenoldopam -- A Selective Peripheral Dopamine-Receptor Agonist for the Treatment of Severe Hypertension N. Engl. J. Med., November 22, 2001; 345(21): 1548 - 1557. [Full Text] [PDF]

				C. M. Sehgal, P. H. Arger, A. C. Silver, J. A. Patton, H. M. Saunders, A. Bhattacharyya, and C. P. Bell Renal Blood Flow Changes Induced with Endothelin-1 and Fenoldopam Mesylate at Quantitative Doppler US: Initial Results in a Canine Study Radiology, May 1, 2001; 219(2): 419 - 426. [Abstract] [Full Text]

				J. Varon and P. E. Marik The Diagnosis and Management of Hypertensive Crises Chest, July 1, 2000; 118(1): 214 - 227. [Abstract] [Full Text] [PDF]

				T. Hussain and M. F. Lokhandwala Renal Dopamine Receptor Function in Hypertension Hypertension, August 1, 1998; 32(2): 187 - 197. [Abstract] [Full Text] [PDF]

				W. J. Elliott, W. B. Martin, and M. B. Murphy Comparison of Two Noninvasive Screening Tests for Renovascular Hypertension Arch Intern Med, March 22, 1993; 153(6): 755 - 764. [Abstract] [PDF]

				D. D. Gretler, W. J. Elliott, M. Moscucci, R. W. Childers, and M. B. Murphy Electrocardiographic Changes During Acute Treatment of Hypertensive Emergencies With Sodium Nitroprusside or Fenoldopam Arch Intern Med, December 1, 1992; 152(12): 2445 - 2448. [Abstract] [PDF]

				A NEW THERAPY FOR HYPERTENSIVE CRISIS Journal Watch (General), March 30, 1990; 1990(330): 8 - 8. [Full Text]